Astellas Gene Therapies

     Drug: AT466

     Approach: AAV-antisense

     Status: Preclinical.  

     Company website explaining AT466.

     April 8, 2019 Press Release announcing collaboration with Nationwide Children's Hospital

    Dec. 2021 Press Release announcing collaboration with Dyno for viral vector delivery technology.